ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 2063 • ACR Convergence 2022

    Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus

    Alfredo Aguirre1, Kimberly DeQuattro2, Patricia Katz3, Kurt Greenlund4, Kamil Barbour4, Caroline Gordon5, Cristina M Lanata6, Lindsey Criswell7, Maria Dall'Era8 and Jinoos Yazdany9, 1University of California, San Francisco, San Francisco, CA, 2University of Pennsylvania, Philadelphia, PA, 3UCSF, San Rafael, CA, 4Centers for Disease Control and Prevention, Atlanta, GA, 5Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 6NIH/NHGRI, Washington, DC, 7National Human Genome Research Institute, NIH, Bethesda, MD, 8University of California, Division of Rheumatology, San Francisco, CA, 9UCSF, San Francisco, CA

    Background/Purpose: Medication cost concerns are associated with nonadherence and poor outcomes in the general population. Prior research has described medication cost concerns in up to…
  • Abstract Number: 2081 • ACR Convergence 2022

    COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave

    Amit Saxena1, Alexis Engel2, Brittany Banbury1, Ghadeer Hasan3, Nicola Fraser1, Devyn Zaminski1, Mala Masson4, Rebecca Haberman5, Jose Scher2, Gary Ho6, Jammie Law3, Paula Rackoff1, Chung-E Tseng5, H Michael Belmont1, Robert Clancy1, Jill Buyon7 and Peter Izmirly7, 1NYU School of Medicine, New York, NY, 2New York University School of Medicine, New York, NY, 3NYU Langone, New York, NY, 4NYU Langone Medical Center- Division of Rheumatology, New York, NY, 5NYU Langone Health, New York, NY, 6New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, 7NYU Grossman School of Medicine, New York, NY

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at high risk for severe disease from COVID-19 and decreased vaccine efficacy, due to inherent immune perturbations…
  • Abstract Number: 2101 • ACR Convergence 2022

    Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study

    Ekrem Turk, Vaishali Deenadayalan, Khaldun Obeidat and Pierre Rodriguez, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL

    Background/Purpose: Autoimmune Hemolytic Anemia (AIHA) is one of the manifestations of Systemic lupus erythematosus (SLE), an autoimmune connective tissue disease. AIHA may be present in…
  • Abstract Number: 2225 • ACR Convergence 2022

    Physical Inactivity Is Associated with Increased Expression of T Cell Inflammatory Genes in Systemic Lupus

    Sarah Patterson1, Sebastian Cruz Gonzalez2, Alexandra Tsitsiklis2, Cristina Lanata3, Lenka Maliskova4, Chun Ye1, Zachary Cutts4, Jinoos Yazdany5, Maria Dall'Era6, Lindsey Criswell7, Charles Langelier2, Patricia Katz5 and Marina Sirota8, 1University of California, San Francisco, San Francisco, CA, 2UCSF, San Francisco, CA, 3NIH, Washington, DC, 4University of California, San Francisco, San Francisco, 5UCSF, San Rafael, CA, 6University of California, Division of Rheumatology, San Francisco, CA, 7National Human Genome Research Institute, NIH, Bethesda, MD, 8UCSF, SF

    Background/Purpose: Prior studies show an independent association between greater physical activity and lower inflammatory markers among adults in the general population, but the impact of…
  • Abstract Number: 0062 • ACR Convergence 2022

    Comparing Alzheimer’s Disease Risk in Patients with Chronic Inflammatory Autoimmune Diseases: A Medicare Cohort Study

    Justin Levinson1, Jonathan Katz2, Yi Chen3, W. Ryan Powell4, Andrea Gilmore-Bykovskyi5, Amy J. Kind6 and Christie Bartels7, 1University of Wisconsin School of Medicine and Public Health, Department of Medicine, Rheumatology Division, Madison, WI, 2University of Wisconsin Hospitals and Clinics, Madison, WI, 3University of Wisconsin School of Medicine and Public Health, Department of Medicine, Department of Biostatistics and Informatics, Madison, WI, 4University of Wisconsin School of Medicine and Public Health, Center for Health Disparities Research, Thousand Oaks, CA, 5University of Wisconsin School of Medicine and Public Health, Department of Emergency Medicine; and the Center for Health Disparities Research, Madison, WI, 6University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division & Center for Health Disparities Research, Madison, WI, 7University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Chronic inflammatory diseases have been associated with an increased risk of Alzheimer’s disease (AD), yet emerging research in rheumatoid arthritis (RA) and psoriasis suggests…
  • Abstract Number: 0115 • ACR Convergence 2022

    Facilitators of Immunosuppressive Medication Adherence in Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers and Clinic Staff

    Shannon Herndon1, Amy Corneli2, Carrie Dombeck3, Teresa Swezey3, Megan Clowse3, Jennifer Rogers4, Lisa Criscione-Schreiber2, Rebecca Sadun3, Jayanth Doss3, Amanda Eudy5, Hayden Bosworth2 and Kai Sun3, 1Duke University Hospital, Durham, NC, 2Duke University School of Medicine, Durham, NC, 3Duke University, Durham, NC, 4Duke, Durham, NC, 5Duke University, Raleigh, NC

    Background/Purpose: SLE disproportionately affects patients of color. Medication nonadherence is more common among patients of color with SLE and is associated with worse health outcomes.…
  • Abstract Number: 0328 • ACR Convergence 2022

    Predicting Progression from Undifferentiated to Definitive Connective Tissue Diseases: A Systematic Review and Meta-analysis

    Sarah Dyball1, Mia Rodziewicz1, Claudia Mendoza Pinto2, Ian N. Bruce3 and Ben Parker4, 1The University of Manchester, Manchester, United Kingdom, 2Systemic Autoimmune Diseases Research Unit, High-Specialty Medical Unit-CIBIOR, Mexican Social Security Institute, Puebla, Mexico, 3Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 4Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom

    Background/Purpose: Undifferentiated connective tissue disease (UCTD) encapsulates a broad range of conditions including incomplete forms of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), some…
  • Abstract Number: 0346 • ACR Convergence 2022

    Improving Eye Screening Compliance in Patients Taking Hydroxychloroquine in a Community Hospital Setting

    George Gennaoui1, Sana Kang2 and J. Patricia Dhar3, 1Ascension St. John Hospital, St. Clair Shores, MI, 2Ascension St John Hospital, Chesterfield, MO, 3Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI

    Background/Purpose: Hydroxychloroquine (HCQ) is a medication used in most patients with systematic lupus erythematous (SLE). It is generally a safe; however, it can cause retinal…
  • Abstract Number: 0368 • ACR Convergence 2022

    Which Are the Best Therapeutic Strategies for Systemic Lupus Erythematosus Severe Thrombocytopenia? A Ten Year Analysis

    Erik Cimé-Aké, Ana Barrera-Vargas, Roberta Demichelis-Gómez, Martha Ramírez-Alemón and Marina Rull-Gabayet, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico

    Background/Purpose: Severe thrombocytopenia in systemic lupus erythematosus (SLE) is characterized by poor response to glucocorticoids and frequent relapses. Information regarding the risk of relapse with…
  • Abstract Number: 0633 • ACR Convergence 2022

    Identification of Systemic Lupus Erythematosus Endotypes by Analysis of Inflammatory and Immunologic Gene Expression Signatures

    Erika Hubbard1, Prathyusha Bachali2, Kathryn Kingsmore Allison1, Yisha He1, Michelle Catalina3, Amrie Grammer4 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2AMPEL BioSolutions, Redmond, WA, 3AMPEL BioSolutions, Harvard, MA, 4AMPEL LLC, Charlottesville, VA

    Background/Purpose: One of the hallmarks of SLE is clinical and molecular heterogeneity. Recent work has leveraged next-generation sequencing techniques to identify molecular signatures characteristic of…
  • Abstract Number: L02 • ACR Convergence 2021

    COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases

    Ines Colmegna1, Mariana Useche1, Emmanouil Rampakakis2, Nathalie Amiable3, Emmanuelle Rollet-Labelle3, Louis Bessette4, Jo-Anne Costa4, Marc Dionne4, Mary-Ann Fitzcharles2, Elizabeth Hazel2, Deirdre McCormack2, Laetitia Michou4, Pantelis Panopalis2, Marc-Andre Langlois5, Sasha Bernatsky6 and Paul R. Fortin7, 1The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2McGill University Health Centre, Montreal, QC, Canada, 3Centre de Recherche du CHU de Quebec, Quebec, Canada, 4Universite Laval, Quebec, QC, Canada, 5University of Ottawa, Ottawa, ON, Canada, 6McGill University, Montreal, QC, Canada, 7CHU de Quebec - Universite Laval, Quebec, Canada

    Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
  • Abstract Number: L03 • ACR Convergence 2021

    COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine

    Kyriakos Kirou and Jeffrey Zhang-Sun, Hospital for Special Surgery, New York, NY

    Background/Purpose: Optimal COVID-19 vaccine responses are necessary to protect against severe infection. Patients with systemic rheumatic diseases (SRD) are at risk for not mounting adequate…
  • Abstract Number: L08 • ACR Convergence 2021

    Association of Limited Health Literacy with Clinical and Patient-Reported Outcomes in Systemic Lupus Erythematosus: An Analysis from the Peer Approaches to Lupus Self-Management (PALS) Program

    Mithu Maheswaranathan1, Andrea Boan2, Viswanathan Ramakrishnan2, Hetlena Johnson3, Jillian Rose-Smith4, Clara Dismuke-Greer5, Leonard Egede6, Jim Oates2 and Edith Williams2, 1Duke University, Durham, NC, 2Medical University of South Carolina, Charleston, SC, 3LupusCSC, Columbia, SC, 4Hospital for Special Surgery, New York, NY, 5VA Palo Alto, Palo Alto, CA, 6Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Health literacy (HL) is an important social determinant of health defined as the ability to understand and use health information.  Limited HL is associated…
  • Abstract Number: L13 • ACR Convergence 2021

    Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study

    Cynthia Aranow1, Cornelia Allaart2, Zahir Amoura3, Ian N Bruce4, Patricia Cagnoli5, Richard Furie1, Paul Peter Tak6, Murray Urowitz7, Ronald van Vollenhoven8, Kenneth L Clark6, Mark Daniels9, Norma Lynn Fox10, Yun Irene Gregan10, James Groark11, Robert B Henderson9, Mary Oldham9, Don Shanahan9, Andre van Maurik9, David A Roth10 and YK Onno Teng2, 1Feinstein Institutes for Medical Research, Northwell Health, Great Neck, NY, 2Leiden University Medical Center, Leiden, Netherlands, 3Centre National de reference pour le Lupus, Service de Medecine Interne 2, Institut E3M, Hopital Pitié-Salpétrière, Paris, France, 4NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Trust and Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 5University of Michigan Medical Center, Ann Arbor, MI, 6GlaxoSmithKline (At the time of the author's contribution to this study), Stevenage, United Kingdom, 7Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, 8Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 9GlaxoSmithKline, Stevenage, United Kingdom, 10GlaxoSmithKline, Collegeville, PA, 11GlaxoSmithKline (At the time of the author's contribution to this study), Collegeville, PA

    Background/Purpose: Disease control remains an unmet need in SLE. The rationale for sequential BEL and RTX therapy in SLE was previously published.1 This study evaluated…
  • Abstract Number: 0006 • ACR Convergence 2021

    Metabolic Characteristics of Age-related B Cells in Lupus-prone Mice and Effects on Follicular Helper T Cells

    Ivan Ramirez1, Betty Diamond2 and Sun Jung Kim3, 1Northwell, Little Neck, NY, 2Northwell Health, Manhasset, NY, 3Feinstein Institutes for Medical Research, Manhasset, NY

    Background/Purpose: Since the description of age-associated B cells (ABC), there has been a growing interest in the role of these cells in autoimmunity. Evidence suggests…
  • « Previous Page
  • 1
  • …
  • 84
  • 85
  • 86
  • 87
  • 88
  • …
  • 150
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology